Real-world outcomes and complications of different surgical approaches for significant submacular haemorrhages

Purpose: To evaluate the outcomes and complications after different surgical management of cases with significant sumacular hemorrhage (SMH) of size more than 4 disc diameter (DD). Methods: It was a retrospective interventional study. All consecutive 103 cases of significant SMHs were treated by vitrectomy and divided into three groups. In Group A (<4 weeks, confined to the macula or extending inferiorly, n = 62), vitrectomy, subretinal cocktail of tissue plasminogen activator (tPA), antivascular endothelial growth factor, and air with SF6 gas; in Group B (4–8 weeks, extending beyond macula, n = 31), subretinal tPA followed by SMH drainage either by retinotomy (Group B?1, n = 17) or by temporal 180?degree retinectomy (Group B?2, n = 14) with silicone oil (SO) tamponade; and in Group C (>8 weeks, extending beyond macula, n = 10), SMH removal with autologous retinal pigment epithelium (RPE)?Choroid patch graft transplantations with SO tamponade were performed. Parameters evaluated were best corrected visual acuity (BCVA), Optos, optical computerized tomography, and ultrasonography as required. Results: Significant visual improvement was seen from mean preoperative to mean postoperative BCVA in Group A (P < 0.001), Group B (P < 0.001), and Group C (P < 0.001). Postoperative complications were recurrent SMH (4.84% vs 12.90% vs 10%), vitreous hemorrhage (6.45%, GroupA), hyphema (4.84% vs 12.90% vs 10%), hypotony (nil vs 3.23% vs 20%), macular hole formation (6.45%, Group A), epiretinal membrane (16.13%, Group B), and retinal detachment (3.23%, Group A and 10%, Group C). Conclusion: Surgical approaches for significant submacular hemorrhage are visually awarding, though certain specific complications may arise

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study

Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab?induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. Results: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two?thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre?IOI levels by 3 months’ time point. Conclusion: Brolucizumab?induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab.

Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes � A multicenter retrospective study

Purpose: To report the initial experience of managing treatment?resistant and treatment?na飗e eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. Methods: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti?VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a pro re nata (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study. Results: We included 21 eyes of 21 patients with PCV with a mean age of 65.1 � 9.9 years, of which 16 eyes (76%) were treatment?resistant. The mean follow?up period from receiving the first brolucizumab was 27.3 � 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow?up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection?free interval was 12 � 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47�logMAR) and improved to 0.3 logMAR (IQR = 0.25�6 logMAR), whereas the mean macular thickness improved from 443 � 60 ?m at baseline to 289 � 25 ?m (P < 0.001) at the last follow?up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions. Conclusion: Brolucizumab is safe and effective in controlling PCV disease in both treatment?resistant and treatment?na飗e eyes

Psychiatric Co-morbidities Among Patients of Globus Hytericus Attending ENT OPD of a Tertiary Care Hospital.

Globus hystericus is a functional esophageal disorder, contributes a significant portion of ENT referral. Severe incapacitating symptoms of globus invariably compromise their quality of life which is further hampered by associated psychiatric co-morbidities. But in literature, conflicting results were reported regarding the pattern of psychiatric co-morbidities. Method: In an observational cross sectional study 53 consecutive consenting patients (N=53) of globus diagnose by criteria of R E Clouse, attending to the Department of ENT of tertiary care hospital of Eastern part of India were referred to Psychiatry OPD and screened for psychiatric comorbidities using Mini International Neuropsychiatric Interview (MINI) English Version 5.0.0 and confirmed by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). Result: 79.25 % (n=42) of globus patients had psychiatric co-morbidities which was significantly higher (p<0.05, odds ratio 14.02) than their relatives attending with the patients. Among the patients of globus, 32.01% (n=17) had multiple diagnoses. Major depressive disorder was found in 43.04% (n=23), obsessive compulsive personality disorder in 16.98% (n=9), undifferentiated somatoform disorder in 13.21% (n=7), generalized anxiety disorder and panic disorder with agoraphobia each in 9.43% (n=5), borderline personality disorder in 7.55% (n=4), obsessive compulsive disorder and dysthymia each in 3.77% (n=2) and hypochondriasis in 1.89% (n=1). No association was found between presence of psychiatric morbidity and socio-demographic variables of the globus patients. Conclusion: Burden of psychiatric co-morbidities among the patients of globus is quiet high. So, they should be regularly screened for psychiatric illness and an integrated treatment approach can be taken for them to get the opportunity of effective psychopharmacological and behavioral approaches.